SCANDION ONC. DK-0735
Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for tr… Read more
SCANDION ONC. DK-0735 (8VY) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, SCANDION ONC. DK-0735 (8VY) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
SCANDION ONC. DK-0735 - Net Assets Trend (None–None)
This chart illustrates how SCANDION ONC. DK-0735's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SCANDION ONC. DK-0735 (None–None)
The table below shows the annual net assets of SCANDION ONC. DK-0735 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to SCANDION ONC. DK-0735's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
SCANDION ONC. DK-0735 Competitors by Market Cap
The table below lists competitors of SCANDION ONC. DK-0735 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Maj Invest - High Income Obligationer
CO:MAJHIO
|
$143.69K |
|
LookSmart Group Inc
PINK:LKST
|
$143.72K |
|
MANCHESTER UTD A
MU:MUF
|
$143.76K |
|
Godsinlosen Nordic AB
ST:GIAB
|
$143.79K |
|
Photomyne Ltd
TA:PHTM
|
$143.33K |
|
APT Systems Inc
PINK:APTY
|
$143.25K |
|
Electronic Systems Technology Inc
PINK:ELST
|
$143.20K |
|
Australian Oilseeds Holdings Limited Warrant
NASDAQ:COOTW
|
$143.09K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SCANDION ONC. DK-0735's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares SCANDION ONC. DK-0735's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently SCANDION ONC. DK-0735 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares SCANDION ONC. DK-0735's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SCANDION ONC. DK-0735 (8VY) | €- | N/A | N/A | $143.45K |
| Hanna Capital Corp (04U1) | $-79.29K | 0.00% | 0.00x | $116.52K |
| WESTMINSTER RES (08W) | $4.66 Million | -31.33% | 0.12x | $5.16 Million |
| Axonics Inc (0I3) | $570.14 Million | -10.47% | 0.16x | $3.29 Billion |
| Global Bioenergies SA (1DK) | $14.81 Million | -86.04% | 0.89x | $369.68K |
| GIEAG Immobilien AG (2GI) | $41.80 Million | 40.21% | 8.93x | $15.57K |
| 2invest AG (2INV) | $82.61 Million | -2.29% | 0.06x | $13.67 Million |
| PT Central Proteina Prima Tbk (4PT) | $3.42 Trillion | 11.74% | 1.00x | $6.90 Million |
| DGH Deutsche Grundwert Holding AG (5TR) | $0.00 | 0.00% | 0.00x | $18.45K |
| SOFTCHOICE CORP. (90Q) | $58.23 Million | -19.76% | 10.01x | $470.36 Million |
| ALBA SE (ABA) | $142.95 Million | 5.25% | 0.45x | $5.10 Million |